Egetis Therapeutics Launches EMCITATE in the U.S.
Egetis Therapeutics announced the U.S. launch of EMCITATE for patients with MCT8 deficiency. The company says it is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pe